Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 6.75 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Genentech, Inc., Incyte Corporation, and Novartis Pharmaceuticals Corporation.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

12th Annual International Symposium on Melanoma and Other Cutaneous Malignancies Resources

12th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®


PER Pulse™ Recap

Resources

Community Practice Connections™: 12th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
Earn up to 2.0 AMA PRA Category 1 Credits™
Community Practice Connections™: 12th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® consists of a series of interactive clinical vignettes, short video interviews of leading experts in melanoma and other cutaneous malignancies, and short summaries of clinical data related to these malignancies. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

PER Pulse™ Recap
The 12th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®, which was held February 20, 2016, featured internationally recognized experts in dermatologic malignancies discussing best practices and new approaches for the treatment of patients with melanoma.



PER Pulse™ Recap

PER Pulse™ Recap
 


1 of 3
PER Pulse™ Recap
Update on Immunotherapy in Patients with Advanced Melanoma

The 12th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®, which was held February 20, 2016, featured internationally recognized experts in dermatologic malignancies discussing best practices and new approaches for the treatment of patients with melanoma. This first of 3 PER Pulse™ Recaps focuses on current and future approaches with immunotherapy for patients with advanced disease, as presented by Tara Gangadhar, MD, and Michael Postow, MD.

  • Immune checkpoint inhibitors
    • Monotherapy: For the first-line treatment of patients with unresectable or metastatic melanoma, treatment with a regimen containing a PD-1 checkpoint inhibitor is preferred over ipilimumab. Current options include nivolumab, based on the phase III CheckMate 066 trial of nivolumab versus dacarbazine, and pembrolizumab, based on KEYNOTE-002 and KEYNOTE-006, which demonstrated superiority of pembrolizumab over chemotherapy or ipilimumab, respectively.
    • Combinations: The combination of nivolumab with ipilimumab has received accelerated approval for unresectable or metastatic melanoma based on the CheckMate 067 trial comparing ipilimumab to either single-agent nivolumab or nivolumab plus ipilimumab. Both single-agent nivolumab and the combination arm demonstrated superior response and progression-free survival compared with ipilimumab.
  • Other approaches to immunotherapy
    • Talimogene laherparepvec, approved in October 2015, is an engineered oncolytic virus that both directly kills tumor cells and secretes granulocyte-macrophage colony-stimulating factor to stimulate the immune system. Treatment is administered locally and is indicated for patients with unresectable cutaneous, subcutaneous, or nodal lesions, as well as in those whose disease recurs after initial surgery.
    • Several other molecules related to immune function, including indoleamine 2,3-dioxygenase (IDO), CD134, and glucocorticoid-induced TNFR-related protein (GITR) are under investigation as therapeutic targets.

2 of 3
PER Pulse™ Recap
Targeted Agents for Patients with Unresectable or Metastatic Melanoma

The 12th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®, which was held February 20, 2016, featured internationally recognized experts in dermatologic malignancies discussing best practices and new approaches for the treatment of patients with melanoma. This second of 3 PER Pulse™ Recaps focuses on targeted combinations for patients with unresectable or metastatic melanoma, as presented by Jeffrey Weber, MD, PhD, and Jason Luke, MD, FACP.

  • BRAF-mutant melanoma: Combination therapy with a BRAF inhibitor and a MEK inhibitor is preferred over single-agent therapy with a BRAF inhibitor in patients with unresectable or metastatic melanoma and a BRAF mutation. Randomized phase III trials (COMBI-d, COMBI-v, coBRIM) showed improved efficacy with combination therapy, as well as a reduced incidence of cutaneous squamous cell carcinoma compared with BRAF inhibitor monotherapy. Approved combinations include dabrafenib plus trametinib and vemurafenib plus cobimetinib.
  • NRAS-mutant melanoma: In patients with unresectable or metastatic melanoma and an NRAS Q61 mutation, single-agent binimetinib yielded improved progression-free survival and response compared with dacarbazine in the phase III NEMO trial. These data have been filed in a New Drug Application with the US Food and Drug Administration.

3 of 3
PER Pulse™ Recap
Treatment for Patients With Non-Melanoma Cutaneous Malignancies

The 12th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®, which was held February 20, 2016, featured internationally recognized experts in dermatologic malignancies discussing best practices and new approaches for the treatment of patients with melanoma. This third of 3 PER Pulse™ Recaps focuses on therapeutic options for patients with other cutaneous malignancies, as presented by Jason Luke, MD, FACP.

  • Basal cell carcinoma (BCC): Abnormal activation of the Hedgehog (Hh) signaling pathway is observed in patients with BCC. Based on nonrandomized, phase II trials, the Hh pathway inhibitors vismodegib and sonidegib have been approved for patients with recurrent BCC that is not amenable to surgery or radiation therapy.
  • Merkel cell carcinoma (MCC): A rare subtype of skin cancer, MCC is associated with Merkel cell polyomavirus in approximately 80% of cases. The expression of PD-1 on approximately 50% of the tumor-infiltrating lymphocytes in patients with MCC has provided the rationale for exploring immune checkpoint inhibitors in this disease. In 25 patients with MCC and no prior systemic therapy, pembrolizumab yielded responses in 56% of the patients. The anti-PD-L1 antibody avelumab has been investigated in patients with pretreated MCC, demonstrating responses in 32% of 88 patients.


Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity is not approved for AMA PRA Category 1 Credit™.

Supported by educational grants from Genentech, Inc, Incyte Corporation, and Novartis Pharmaceuticals Corporation.






Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
1234567
891011121314
15161718192021
22232425262728
293031
Filter By